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through siRNA-IRF5 Gene Delivery
with Homing Peptides to Microglia
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Science, Shiga, Japan; 3Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 4Division of Anatomy and Cell Biology, Shiga University of Medical
Science, Shiga, JapanAstrocyte- and microglia-targeting peptides were identiﬁed
and isolated using phage display technology. A series of proced-
ures, including three cycles of both in vivo and in vitro
biopanning, was performed separately in astrocytes and in
M1 or M2 microglia, yielding 50–58 phage plaques in each
cell type. Analyses of the sequences of this collection iden-
tiﬁed one candidate homing peptide targeting astrocytes
(AS1[C-LNSSQPS-C]) and two candidate homing peptides
targeting microglia (MG1[C-HHSSSAR-C] and MG2[C-
NTGSPYE-C]). To determine peptide speciﬁcity for the target
cell in vitro, each peptide was synthesized and introduced into
the primary cultures of astrocytes or microglia. Those peptides
could bind to the target cells and be selectively taken up by the
corresponding cell, namely, astrocytes, M1 microglia, or M2
microglia. To conﬁrm cell-speciﬁc gene delivery to M1 micro-
glia, the complexes between peptide MG1 and siRNA-inter-
feron regulatory factor 5 were prepared and intrathecally
injected into a mouse model of neuropathic pain. The com-
plexes successfully suppressed hyperalgesia with high efﬁciency
in this neuropathic pain model. Here, we describe a novel gene
therapy for the treatment neuropathic pain, which has a high
potential to be of clinical relevance. This strategy will ensure
the targeted delivery of therapeutic genes while minimizing
side effects to non-target tissues or cells.Received 8 August 2017; accepted 21 February 2018;
https://doi.org/10.1016/j.omtn.2018.02.007.
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Homing peptides that selectively target many kinds of tissues have
been identiﬁed and have received a great deal of attention for their po-
tential application in cell-speciﬁc or tissue-speciﬁc delivery of drugs
and genes by coupling and assembling into novel complexes.1,2 These
peptides are very short and typically consist of only 3 to 12 amino
acids.1,3 However, these peptides exhibit strong afﬁnities and unique
speciﬁcities against target ligands, such as the Arg-Gly-Asp (RGD)
motif against av-integrins.4,5 By insertion of the homing peptides
into viral vectors, tissue-speciﬁc targeting viral vectors can be pro-
duced for use in gene therapy and peptide-mediated drug delivery
systems.6–9 These tissue-speciﬁc viral vectors provide high transduc-
tion efﬁciency, and infected cells undergo a 100-fold increase in divi-Molecular T
This is an open access article under the CC BY-NC-sion efﬁciency of the objective genes.9 These homing peptides were
identiﬁed by in vivo or in vitro phage display screening.10 M13 ﬁla-
mentous phages are used as the platform of the library, and they pre-
sent short random peptides into a minor coat protein (pIII).10 The
speciﬁc cell- or tissue-binding peptides are isolated by a binding-se-
lection procedure, referred to as biopanning with phage.2
We had previously identiﬁed cell-speciﬁc homing peptides to target
neurons in the dorsal root ganglion (DRG) in mice.11 Three kinds of
peptides homing to DRG were lined up and recognized the different
sizes of the neurons.11 Furthermore, those peptides were inserted
into helper-dependent adenovirus vectors, known as gutless adeno-
viral vectors, and developed for clinical use. Building upon these ﬁnd-
ings, we established a novel technology of DRG-targeted tissue-speciﬁc
gene therapy.9 Thus, homing peptides have a high potential for appli-
cability toward, and being a powerful tool for, drug and gene delivery.
Here, phage display technology was applied to identify speciﬁc pep-
tide motifs that recognized astrocytes and microglia. A combination
of in vivo phage display in the spinal cord of mice and in vitro phage
display in cultured cells identiﬁed peptides of interest that were then
combined with small interfering RNA (siRNA) oligonucleotides for
testing the capability of therapeutic gene delivery. Astrocytes and
microglia in the spinal cord are potential targets for the treatment
of many neurological diseases, such as motor neuron disease, spinal
injury, spastic paraplegia, multiple sclerosis, sensory ataxia, and
neuropathic pain.12–18
Studies have shown that interferon regulatory factor 5 (IRF5) is
involved in the pathogenesis of neuropathic pain.19,20 Speciﬁcally,
IRF5 plays an important role in the pathogenesis of tactile allodyniaherapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The Author(s). 203
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Scheme for Screening Homing Peptides
Targeting Astrocytes or Microglia
In vivo (left) and in vitro (right) screening of homing pep-
tides with phage display methods. After three rounds of
in vivo panning, three additional cycles of in vitro panning
were performed. TU, titer unit.
Molecular Therapy: Nucleic Acidsinduced by nerve injury, but not in that of allodynia involved with
general sensations, such as thermal or movement allodynia.20 IRF5
is mainly expressed in M1 microglia21 and is upregulated by spinal
nerve injury, which induces the expression of ATP receptors, such
as the P2X4 receptor, to activate microglia and signal neuropathic
pain in the spinal cord.19,20 Therefore, we hypothesized that downre-
gulation of IRF5 expression in microglia will lead to a reduction in
neuropathic pain.With the ability to achieve targeted delivery of ther-
apeutic genes to microglia in the spinal cord, homing peptides are
considered powerful tools with potential for the discovery and design
of diagnostic agents and novel therapeutics.
In this study, homing peptides to astrocytes and microglia were iden-
tiﬁed. Delivery of siRNA for the IRF5 gene by these homing peptides
highlighted their potential application in the treatment of disease
when combined with therapeutic siRNA oligonucleotides.
RESULTS
Phage Display Screening of Homing Peptides Targeting
Astrocytes and Microglia
After three rounds of in vivo phage display inmice and three rounds of
in vitro phage display using KT-5 cells (astrocytes), 6-3 cells (M1; pro-
inﬂammatory microglia), or Ra2 cells (M2; anti-inﬂammatory micro-
glia), the DNA sequences were analyzed in phages with high afﬁnities
for astrocytes or microglia (Figure 1). The homing peptides targeting
astrocytes were detected in six types of sequences (AS1–AS6) after
three in vivo and three in vitro pannings. The AS1(C-LNSSQPS-C)
peptide was the most frequent in those six types of homing peptides
and was observed in 48 of the 58 phage plaques (frequency, 83%)
(Table 1). In total microglia, 55 types of homing peptides were identi-
ﬁed by the phage display screening. Thirty-one homing peptides
(microglia-speciﬁc peptide [MG] 1–MG31) recognized M1-type mi-
croglia, and 30 peptides (MG1–MG3, MG8–MG10, and MG32–
MG55) recognized M2-type microglia. In addition, 6 homing peptides
(MG1–MG3 and MG8–MG10) were observed in both M1- and M2-
type microglia (Table 1). The MG1(C-HHSSSAR-C) peptide was
observed in 13 of the 51 phage plaques, most frequently in M1-type204 Molecular Therapy: Nucleic Acids Vol. 11 June 2018microglia, and was concurrently observed in 7
of the 50 phage plaques in M2-type microglia
(Table 1). The next most frequent peptide
sequence was MG2(C-NTGSPYE-C), which
was present in 3 of the 51 plaques in M1-type
microglia, was recognized at the highest fre-
quency in M2-type microglia, and was observed
in 8 of the 50 phage plaques (Table 1). The
AS3(C-RGATPMS-C) peptide was present in 2of the 58 phage plaques in astrocytes; it was observed in 1 of the 51
phage plaques in M1-type microglia and 1 of the 50 phage plaques
in M2-type microglia. This peptide was also listed as MG10 in micro-
glia homing peptides. Among all of them, AS1, MG1, and MG2 were
strongly considered candidate homing peptides for targeting astro-
cytes, M1 microglia, and M2 microglia, respectively, and these three
peptides were used for the additional analyses.
High Affinities and Specificities of AS1, MG1, and MG2 Peptides
Targeting Cultured Cells
To determine the speciﬁcities of AS1, MG1, and MG2 against target
cells, each synthesized peptide labeled with ﬂuorescein isothiocyanate
(FITC) was individually introduced into NSC-34 cells (neuron), pri-
mary cultured astrocytes, andmicroglia at a concentration of 1 mg/mL
for 24 hr. AS1 peptides overlapped with glial ﬁbrillary acidic protein
(GFAP) immunostaining and were only observed in astrocytes, but
not withMAP2 staining in neurons or Iba1 staining in microglia (Fig-
ure 2A). Among the GFAP-positive astrocytes, 80% were FITC pos-
itive, including the cells labeled in the partial area or only small spots
(Figures 2A and 2B). 20% of GFAP-positive cells were not labeled
with FITC. In addition, in those astrocytes labeled with AS1 peptides,
various staining patterns were observed.
The afﬁnities of MG1 and MG2 peptides are presented in Figure 3.
MG1 peptides were mainly present in Iba1-positive microglia, and
approximately 60% of microglia were labeled with MG1 peptides (Fig-
ures 3A and 3C). FITC-positive cells were not observed inNSC-34 cells
or astrocytes upon MG1 administration. In the MG2 condition, the
same pattern was observed. FITC ﬂuorescence was observed only in
the primary cultured microglia, not in the NSC-34 cells or astrocytes
(Figure 3B). The population of MG2-labeled microglia was approxi-
mately 40%, which was lower than that in MG1 peptides (Figure 3C).
Characterization of Cell Types Targeted by MG1 and MG2
Peptides
After introducing MG1 and MG2 peptides to microglia, immunoﬂu-
orescent experiments were performed with anti-CD86 (M1) and
Table 1. Amino Acid Sequence of Astrocytes and Microglia (M1- and M2-
Type)-Specific Homing Peptides and the Frequency of Phage Plaque
Amino-Acid Sequence Frequency/Total
Astrocyte Homing Peptides
AS1 C-LNSSQPS-C 48/58
AS2 C-TMSAASH-C 5/58
AS3 C-RGATPMS-C 2/58
AS4 C-FPSHNMH-C 1/58
AS5 C-NHQPSEG-C 1/58
AS6 C-ASPFLCP-C 1/58
Microglia Homing Peptides
M1 Type M2 Type
MG1 C-HHSSSAR-C 13/51 7/50
MG2 C-NTGSPYE-C 3/51 8/50
MG3 C-QTQNRSA-C 3/51 4/50
MG4 C-ANATCPA-C 2/51 0/50
MG5 C-GSKNSAV-C 2/51 0/50
MG6 C-NGGTPNR-C 2/51 0/50
MG7 C-LKLGEKW-C 2/51 0/50
MG8 C-HHRAGVL-C 1/51 2/50
MG9 C-HNETQKM-C 1/51 1/50
MG10 C-RGATPMS-C 1/51 1/50
MG11 C-DLNSDTQ-C 1/51 0/50
MG12 C-DNPDRRK-C 1/51 0/50
MG13 C-DDADQSR-C 1/51 0/50
MG14 C-DFPSRGQ-C 1/51 0/50
MG15 C-DGHDQSL-C 1/51 0/50
MG16 C-EHSRPMS-C 1/51 0/50
MG17 C-GPMSSKS-C 1/51 0/50
MG18 C-LDLPNAM-C 1/51 0/50
MG19 C-LNSRQPS-C 1/51 0/50
MG20 C-MAPHSRV-C 1/51 0/50
MG21 C-MCNSFTW-C 1/51 0/50
MG22 C-NDSDTYT-C 1/51 0/50
MG23 C-NTDAHRA-C 1/51 0/50
MG24 C-QGERWMQ-C 1/51 0/50
MG25 C-QQSMDPA-C 1/51 0/50
MG26 C-SQLPWYS-C 1/51 0/50
MG27 C-SDARSPK-C 1/51 0/50
MG28 C-THGLTAS-C 1/51 0/50
MG29 C-TQSSAMS-C 1/51 0/50
MG30 C-TAKGLQA-C 1/51 0/50
MG31 C-TCNQMAG-C 1/51 0/50
MG32 C-MARYMSA-C 0/51 2/50
MG33 C-PNSTHRN-C 0/51 2/50
MG34 C-TAHDTNS-C 0/51 2/50
Table 1. Continued
Amino-Acid Sequence Frequency/Total
MG35 C-DLLHRGA-C 0/51 1/50
MG36 C-DFPKLRP-C 0/51 1/50
MG37 C-EFSKFRS-C 0/51 1/50
MG38 C-GKTSENS-C 0/51 1/50
MG39 C-HDLNGSM-C 0/51 1/50
MG40 C-IASVDSK-C 0/51 1/50
MG41 C-IGNSNTL-C 0/51 1/50
MG42 C-LGRTNGQ-C 0/51 1/50
MG43 C-NRSQQPW-C 0/51 1/50
MG44 C-PNMTNQW-C 0/51 1/50
MG45 C-QFSKFRS-C 0/51 1/50
MG46 C-QRATPGH-C 0/51 1/50
MG47 C-RSANIYT-C 0/51 1/50
MG48 C-SNSSLTH-C 0/51 1/50
MG49 C-SPRPTQT-C 0/51 1/50
MG50 C-SWQIGGN-C 0/51 1/50
MG51 C-TTINQKV-C 0/51 1/50
MG52 C-VPNLQGT-C 0/51 1/50
MG53 C-WTDANRD-C 0/51 1/50
MG54 C-YTDANRD-C 0/51 1/50
MG55 C-YPHNTPN-C 0/51 1/50
www.moleculartherapy.organti-CD206 (M2) antibodies to identify the cell type labeled with each
peptide. CD86 (M1)- and CD206 (M2)-positive cells were localized in
total MG1 peptide-labeled microglia at rates of 40% and 26%, respec-
tively (Figure 4). In addition, CD86 (M1) and CD206 (M2) were
observed in 27% and 47% of MG2 peptide-positive cells, respectively
(Figure 4). MG1 and MG2 peptides were both able to label M1- and
M2-type cells; however, the MG1 peptide had greater binding afﬁnity
for CD86 (M1)-positive cells, and the MG2 peptide was predomi-
nantly observed in CD206 (M2)-positive cells (Figure 4). The differ-
ence in frequency between MG1 and MG2 peptides is potentially
useful for cell-speciﬁc targeting in gene delivery or the development
of imaging probes.
In Vivo Targeting of the Spinal Cord by AS1, MG1, and MG2
Peptides
To conﬁrm that these homing peptides can target the speciﬁc cells,
in vivo experiments were performed in mice. A speciﬁed amount
(3 mg) of AS1, MG1, and MG2 peptides labeled with FITC was intra-
thecally injected into mice. After 3 hr, the spinal cords were isolated
frommice, and sections of the spinal cord were analyzed immunohis-
tochemically. The AS1 peptides were represented by green ﬂuores-
cence in the spinal cord and completely overlapped with the GFAP
stain, an astrocyte marker, but not with the Iba1 stain, a microglia
marker (Figure 5, upper two lines). The MG1 and MG2 peptides
overlapped with Iba1, but not with GFAP, and there was a greaterMolecular Therapy: Nucleic Acids Vol. 11 June 2018 205
Figure 2. Characterization of the Cell Type Targeted
by AS1 Peptides
(A) The distribution of FITC-labeled, astrocyte-specific
peptides (AS1; green) with MAP2 immunocytochemistry
(red) in NSC-34 cells (neurons), with GFAP immunocyto-
chemistry (red) in primary culture of astrocytes, and with
Iba1 immunocytochemistry (red) in the primary culture of
microglia after 24 hr of incubation with AS1 peptides (1 mg/
mL). (B) The percentage of FITC-positive astrocytes
binding to an astrocyte-specific peptide (AS1) in all GFAP-
positive cells (red) (n = 6). Scale bars, 100 mm in (A). Error
bar, mean + SD in (B).
Molecular Therapy: Nucleic Acidsaccumulation of MG1 peptides than of MG2 peptides in the spinal
cord tissues (Figure 5, lower four lines). These ﬁndings suggest that
AS1, MG1, and MG2 peptides could successfully target the spinal
cord and its corresponding cells.
Knockdown Effect of Target Genes with MG1 or MG2 Peptides
and siRNA Complex in Microglia
To clarify that the homing peptides have potential as vehicles for
targeted gene delivery, gene delivery experiments were performed
in microglia using the complex of MG1 or MG2 peptides and
siRNA-IRF5. First, MG1-9R (MG1[C-HHSSSAR-C]+GGG+9 argi-
nine residues [R]) or MG2-9R (MG2[C-NTGSPYE-C]+GGG+9R)
peptides were synthesized and bound to siRNA oligonucleotides
(Figure 6A). These complexes were bonded together by electrostatic
interaction because of the negative electric charge of the oligonucle-
otides (Figure 6A). As a preliminary study, electrophoresis of the
complexes was performed (Figure S1). Furthermore, to determine
the appropriate ratio of peptides and siRNA, complexes (peptides
and siRNA) at ratios of 0:1, 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, and 5:0
were prepared and assessed by electrophoresis (Figure S1A). At ra-
tios of more than 3:1, oligonucleotide bands were not observed even
as smear bands in the agarose gel, because the negative electric
charge of the oligonucleotides was neutralized by the binding with
the peptides (Figure S1A). Therefore, a ratio of 3:1 was determined
to be the minimal ratio for peptides to bind to siRNA without a
residue. Next, the electrophoresis of the complexes of siRNA-
IRF5 with MG1-3R (MG1[C-HHSSSAR-C]+GGG+3R), MG1-6R
(MG1[C-HHSSSAR-C]+GGG+6R), or MG1-9R peptides was per-
formed to conﬁrm the binding acuities of arginine residues with
oligonucleotides (Figure S1B). Proportionally, as the number of
arginine residues increased from zero to three, six, or nine, the
oligonucleotide bands became gradually weaker (Figure S1B).
Most MG1-0R peptides labeled with FITC were observed as high
signals near sample application wells in agarose gel, suggesting
that MG1-0R could not bind with siRNA (Figure S1B). Therefore,
nine arginine residues were used for binding between homing pep-
tides and oligonucleotides. The siRNA-IRF5 with MG1-9R or
MG2-9R complexes (siRNA, 66 ng; peptides, 200 ng) were admin-206 Molecular Therapy: Nucleic Acids Vol. 11 June 2018istered to lipopolysaccharide (LPS)-stimulated
microglia, and the levels of IRF5 mRNA
expression were analyzed 3 hr after treatment.The mRNA expression of IRF5 in the MG1-9R+siRNA-IRF5
group signiﬁcantly decreased to 60% of that in the MG1-9R+control
group, whereas the siRNA-IRF5 (no peptide) and MG2-9R+siRNA-
IRF5 groups failed to exhibit similar knockdown effects at low doses
(Figure 6B, upper graph). In addition, the siRNA-only and MG2
groups exhibited knockdown effects only in the high-dose experi-
ments (siRNA, 330 ng; peptides, 1 mg). However, the MG1 group
showed >50% knockdown of IRF5 mRNA expression in high-dose
experiments (Figure 6B, lower graph). The MG1-9R+siRNA-IRF5
group exhibited signiﬁcant knockdown effects compared with
siRNA-IRF5 (no peptide) and MG2-9R+siRNA-IRF5 groups in
both low- and high-dose experiments (Figure 6B). The protein
expression level of IRF5 was analyzed 24 hr after treatment through
immunostaining of IRF5 and was demonstrated to be suppressed in
the MG1 groups compared with the no-peptide and MG2 groups at
both low and high doses (Figure 6C). In addition, the protein
expression level of IRF5 in the MG1 group of the high-dose exper-
iments decreased more than that in the three groups of the low-dose
experiments (Figure 6C). The suppression of IRF5 protein expres-
sion exhibited the same pattern with mRNA knockdown effects,
which were most effective in the MG1-9R+siRNA-IRF5 group,
and a dose response was observed in the no-peptide, MG1, and
MG2 groups (Figures 6B and 6C).
Gene Delivery of siRNA-IRF5 with MG1 Homing Peptides
Targeting Microglia in Neuropathic Pain Mice
Gene therapy was performed for neuropathic pain by the knock-
down of IRF5 using the MG1 peptide+siRNA-IRF5 complex (pep-
tides, 3 mg; siRNA, 1 mg) and the comparative groups, which were
MG2, AS1, and DRG complexes (peptides, 3 mg; siRNA, 1 mg) pre-
pared with the same structure as the complex in Figure 6A. Because
IRF5 is involved not in thermal or movement allodynia but rather in
tactile allodynia, the effects of the complexes were evaluated by
measuring the mechanical threshold with plantar tests. After spinal
nerve transection, the reduction in the mechanical threshold against
neuropathic pain was observed on the ipsilateral side of all mice on
day 2 (Figure 7A). After conﬁrmation of neuropathic pain, a thera-
peutic material was administered to mice through the intrathecal
Figure 3. Characterization of the Cell Type Targeed by MG1 and MG2
Peptides
(A and B) The distribution of FITC-labeled microglia-specific peptides (MG1 in A and
MG2 in B; green) with MAP2 immunocytochemistry (red) in NSC-34 cells (neurons),
with GFAP immunocytochemistry (red) in primary culture of astrocytes, and
with Iba1 immunocytochemistry (red) in primary culture of microglia after 24 hr of
incubation with MG1 or MG2 peptides (1 mg/mL). (C) The percentage of FITC-
positive microglia binding with microglia-specific peptides (MG1 or MG2; n = 6 in
each) in all Iba1-positive cells (red). Scale bars, 100 mm in (A) and (B). Error bars,
mean + SD in (C).
www.moleculartherapy.orgspace on day 3. On days 4, 6, and 10, the mechanical threshold in
the MG1+siRNA-IRF5 group signiﬁcantly increased, whereas the
threshold did not change from the pre-treatment baseline levels inthe untreated control and in the siRNA-IRF5-only groups
(Figure 7A).
In addition, non-target therapy was performed using MG2, AS1,
and DRG peptides (targeting the DRG neuron) with siRNA-IRF5
(peptides, 3 mg; siRNA, 1 mg) and was compared with MG1 peptide
treatment (Figure 7C). Only the MG1 peptide group exhibited a
treatment effect for neuropathic pain; the other group of peptides
did not exhibit even partial therapeutic effects (Figure 7C). There-
fore, high-dose experiments (peptides, 15 mg; siRNA, 5 mg) were
performed by using naked siRNA and MG2+siRNA complexes,
which were compared with the MG1+siRNA group (Figure 7D).
In naked siRNA on day 4 and in MG2+siRNA on days 4, 6,
and 8, signiﬁcant therapeutic effects were observed compared with
the effects of the buffer control, which were partial and brief (Fig-
ure 7D). In addition, the effects in the MG2 peptide group were
signiﬁcantly higher than those in the naked siRNA group on day
8 alone (Figure 7D). This result suggested that the MG2 peptide
had partial targeting potential to M1 microglia. The effect in the
MG1 group was the highest among the four groups (buffer control,
siRNA only, MG1, and MG2) (Figure 7D) and was slightly higher
than that observed in the low-dose experiments, as shown in
Figure 7A.
IRF5 mRNA expression in the spinal cord was upregulated in the
buffer control and siRNA-IRF5 groups (low: siRNA, 1 mg; high:
siRNA, 5 mg) 5 days after nerve transection (Figure 7B). In contrast,
on day 5, the mRNA expression of IRF5 in both low-dose (peptides,
3 mg; siRNA, 1 mg) and high-dose (peptides, 15 mg; siRNA, 5 mg)
MG1+siRNA-IRF5 groups was substantially suppressed to the levels
seen before nerve transection (Figure 7B). The effect in the high-dose
group was signiﬁcantly greater than that in the low-dose group in
MG1+siRNA-IRF5 administration. Simple siRNA-IRF5 injections
slightly suppressed the mRNA expression of IRF5 only in the high-
dose application of siRNA-IRF5, not in the low-dose application (Fig-
ure 7B). The effect of delivery and knockdown of the target gene was
markedly higher in the MG1 peptides groups than in the no-peptide
group (Figure 7B).
Immunohistochemistry experiments were performed using spinal
cord sections from the neuropathic pain mouse model after gene
therapy with MG1-siRNA-IRF5. In low-magniﬁcation pictures of
the spinal cord (Figure 8A, extreme right), many CD86-positive cells
accumulated on the ipsilateral side of the dorsal horn in the spinal
cords, whereas few CD86-positive cells were observed on the contra-
lateral side (Figure 8A). At a high magniﬁcation of the ipsilateral
dorsal horn, numerous CD86-positive, pro-inﬂammatory microglia
(Figure 8A, second column, red) were also observed in all groups (Fig-
ure 8A). The quantitation of immunoﬂuorescent intensities revealed
the same level of CD86 protein expression among control, siRNA,
and MG1+siRNA groups (Figure 8C). However, IRF5 staining (Fig-
ure 8, ﬁrst column, green) was markedly weaker in MG1+siRNA
groups than in the control and siRNA-only groups, and quantitative
analysis indicated the same pattern of IRF5 protein expressionMolecular Therapy: Nucleic Acids Vol. 11 June 2018 207
Figure 4. Characterization of Microglia Targeted by
MG1 and MG2 Peptides
Left: immunocytochemistry of CD86 (A) and CD206 (B)
antibodies (red) in the primary microglia culture binding
with FITC-labeled MG1 or MG2 (green) after 24 hr of in-
cubation with the peptides (1 mg/mL). Right: the percent-
age of CD86-positive (A) or CD206-positive (B) cells (red) in
the microglia labeled with MG1 or MG2 peptides (n = 6 in
each). Scale bars, 100 mm. Error bars, mean + SD. MG,
microglia-specific peptides.
Molecular Therapy: Nucleic Acids(Figures 8A and 8B). Both mRNA and protein levels of IRF5 were
effectively suppressed by the MG1-siRNA-IRF5 complexes (Figures
7B and 8), which could result in the reduction of neuropathic pain
in the mouse models (Figure 7A). Moreover, the reduction efﬁcacy
of the MG1 peptide was the highest among all groups (Figure 7).
These ﬁndings highlight the selective targeting ability of MG1 pep-
tides to deliver siRNA oligonucleotides to microglia in the spinal
cord and may serve as a useful tool for developing novel gene therapy
modalities.
DISCUSSION
Effective gene delivery to selective target astrocytes and microglia
requires the identiﬁcation of homing peptides that can access the
central nervous system. Therefore, in vitro and in vivo bio-
pannings with phage libraries were used in this study to identify
peptides that target astrocytes and microglia. We identiﬁed the
AS1(C-LNSSQPS-C) peptide for astrocytes, which was the most208 Molecular Therapy: Nucleic Acids Vol. 11 June 2018frequent peptide in six types of peptide se-
quences detected in a total of 58 clones. Among
the types of microglia homing peptides, 31 for
M1 type, 30 for M2 type, and 6 for both
M1 and M2 types were detected. The MG1(C-
HHSSSAR-C) and MG2(C-NTGSPYE-C) pep-
tides were identiﬁed as the two most frequent
homing peptides. MG1 exhibited a higher bind-
ing capacity for M1-type microglia than did the
MG2 peptide. In contrast, the MG2 peptide had
a greater binding capacity for M2-type micro-
glia. These results have potential applicability
in cell-selective gene delivery. When the tar-
geted cells consist of several subtypes, such as
in microglia,14 cell-speciﬁc targeting is required
for highly efﬁcient gene therapy or imaging. In
this context, MG1 with siRNA could feasibly be
delivered selectively into CD86-positive cells in
the spinal cord, as was the case in this study,
which resulted in effective gene therapy for
neuropathic pain.
In neuronal tissues, many types of cells function
simultaneously to maintain normal physiolog-
ical conditions and uphold the balance of ho-meostasis.22–26 A single molecule can induce variable cellular effects
depending on the type of cell targeted. For example, brain-derived
neurotrophic factor (BDNF) stimulates neurons to induce cell differ-
entiation or growth.27–29 However, BDNF also induced neuropathic
pain through astrocytes by activating the afferent signals from the pe-
ripheral nerves to the brain after injuries.30,31 In addition to BDNF,
many types of cytokines, such as interleukin (IL)-1, IL-6, and tumor
necrosis factor alpha (TNF-a), have several functions and can stimu-
late many types of cells.32–37 In the anti-TNF-a antibody therapy for
rheumatoid arthritis or inﬂammatory bowel syndrome, the target tis-
sue is the articular cavity or intestinal tract.38,39 However, it occasion-
ally induces a compromised host because the drug is systemically
administered.38 Therefore, in the ﬁeld of molecular therapy, it is
crucial that the therapeutic molecule be delivered only to the target
tissues and cells. In addition, this type of precise targeting can sup-
press the side effects of treatment or any unexpected phenomenon,
which is ideal for developing therapeutic agents.
Figure 5. In Vivo Targeting of the Spinal Cord by AS1, MG1, and MG2
The distribution of FITC-labeled, astrocyte-specific peptides (AS1; green) with
GFAP or Iba1 stain (red) (upper two lines) or FITC-labeled microglia-specific pep-
tides (MG1 or MG2; green) with GFAP or Iba1 stain (red) (lower four lines) in the
spinal cord sections at 3 hr after injection of AS1, MG1, or MG2 peptides (3 mg in
10 mL of PBS). Scale bars, 100 mm.
www.moleculartherapy.orgAn important consideration when transferring drugs into cells is
which of the many types of cell penetration peptides can be used
for delivery into target cells.40,41 Classically, the transactivator of tran-scription protein in HIV-1 was identiﬁed to be related to the translo-
cation of proteins through the cell membrane.42,43 An additional
study demonstrated that polyarginine could transfer to the cell mem-
brane because of the positive electric charge, which could bind to pro-
teoglycan with a negative electric charge.44 In this study, nine arginine
residues were connected to the MG1 homing peptide. This modiﬁca-
tion resulted in a powerful, high-performance tool for effective gene
therapy. The MG1-9R peptide seems to have high potential as the de-
livery device for speciﬁc cells and cell penetration peptides. These
ﬁndings could be used as a novel approach for the delivery of small
oligonucleotides.
Many antisense oligonucleotides (ASOs) have been developed as the
nucleic acid drugs and used in the trials targeting cancer and other
incurable genetic diseases.45–47 In treatments using ASO, their stabil-
ity is typically the most important problem. By their nature, ASO are
immediately degraded by nuclease in vivo, because ASO is generally a
single-stranded structure.45 Hence, to prevent the degradation of
ASO, chemical modiﬁcations such as locked nucleic acids, 20-O-me-
thoxyethyl RNA, and constrained ethyl BNA have been devised for
their stability.48–51 In addition, the siRNAs have been developed as
a device for novel gene therapy and are slightly more stable than
ASO because of their double-stranded structure.48,52,53 The introduc-
tion of the drug delivery system is necessary for the siRNA gene ther-
apy and requires coating with lipid nanoparticle or liposome, which
were applied to protect siRNA from nuclease exposure.48,53,54 In addi-
tion, we used siRNA duplexes of 25-mer sense and 27-mer antisense,
which are known to exhibit high stability and activity for knockdown
compared with the duplex of 21-mer siRNA.55 The complexes of pep-
tides and siRNA have been reported in several articles,52,56 which
demonstrated the effective gene delivery of siRNA conjugated with
N-acetylgalactosamine (GalNAc) for hepatocytes56 or with rabies
virus glycoprotein (RVG) for acetylcholine receptors.52 In this study,
microglia homing peptides exhibited potential as a delivery device for
siRNA and provided high knockdown efﬁcacy of siRNA, although
this MG1 peptide was shorter and smaller than the GalNAc and
RVG peptides.52,56
Here, we performed gene therapy for neuropathic pain using the
complex formed between short peptides and small oligonucleotides.
In clinical settings, repeat injections are occasionally required for sus-
tained effects of treatment. However, our results provide a novel strat-
egy for selective gene therapy targeted toward nervous system tissues,
which might be safer than gene therapy with virus vectors57–61 or the
chemical materials62,63 used in lipofection. Moreover, intrathecal
injection was used for direct delivery into the spinal cord. This pro-
cedure is routinely performed in clinical settings.64 In addition, local
injection has merit with respect to antibody formation compared
with intravenous systemic injection.60 Therefore, this strategy can
be translated into clinical use for treating patients with neuropathic
pain, although additional safety trials must be performed in vivo.
The IRF5 gene was selected as a therapeutic molecule in this study.
Its expression increases in the microglia of the spinal cord followingMolecular Therapy: Nucleic Acids Vol. 11 June 2018 209
Figure 6. Design of Complexes between Peptides
and siRNAs and Knockdown Effects In Vitro
(A) Scheme of MG1 or MG2 peptide structures and their
binding with siRNA-interferon regulatory factor 5 (IRF5)
oligonucleotides. (B and C) Knockdown effects by a low
dose (peptide, 200 ng; siRNA, 66 ng) or high dose (peptide,
1 mg; siRNA, 330 ng) of the complexes MG1 or MG2+
siRNA-IRF5 in primary microglia. (B) Graphs show relative
mRNA expression of IRF5 in the no-peptide, MG1, or MG2
group at 3 hr after administration of the complexes against
each scrambled control or oligonucleotide group in low-
dose (upper panel) or high-dose (lower panel) experiments
(n = 5 in each group). IRF5 mRNA expression levels were
standardized by b-actin mRNA expression and were
shown as the relative ratio against each control oligonu-
celotide group. *p < 0.05 against the control oligonucleo-
tide group. #p < 0.05. (C) IRF5 immunostainings (red) and
phase images of primary microglia in the siRNA-IRF5
(no peptide), MG1+siRNA-IRF5, or MG2+siRNA-IRF5
group 24 hr after administration of a low or high dose of the
complexes. The graph shows IRF5 immunostaining in-
tensity (n = 5 in each group). *p < 0.05 against the other two
groups in each dose experiment. #p < 0.05. Scale bars,
100 mm in (C). Error bars, mean + SD in (B) and (C). MG,
microglia-specific peptides; Cys, cysteine; A, alanine; E,
glutamate; G, glycine; H, histidine; N, asparagine; P, pro-
line; R, arginine; S, serine; T, threonine; Y, tyrosine.
Molecular Therapy: Nucleic Acidsspinal nerve injury,21,65 which was used to induce neuropathic pain
in the disease model. Therefore, this molecule was well suited to
conﬁrm that microglia homing (MG1) peptides can selectively
deliver the therapeutic gene to M1 microglia. The MG1 peptide
was the most effective for neuropathic pain in all peptide groups.
Surprisingly, only one shot of MG1+siRNA-IRF5 induced a remark-
able knockdown effect with the same expression level of IRF5 in the
pre-treatment condition. According to our in vitro study, MG1
could not bind to all of the microglia. Therefore, IRF5 mRNA might
be strongly suppressed in CD86 cells targeted by MG1+siRNA-IRF5
until the level to offset the IRF5 expression in the untargeted cells.
MG2 groups exhibited a certain level of therapeutic effect only with
the high-dose administration study compared with that of the pep-
tide-control and siRNA-control groups. These results are consistent210 Molecular Therapy: Nucleic Acids Vol. 11 June 2018with the in vitro study results, which indicated
that the MG1 peptide was superior to the
MG2 peptide for targeting M1 microglia,
although the MG2 peptide was bound to a small
population of M1 microglia. In contrast, the
AS1 and DRG groups exhibited no therapeutic
effects for neuropathic pain. These results sug-
gest that the AS1 and DRG peptides could not
target M1 microglia. In addition, it appears
that IRF5 is expressed at low levels in neurons
and astrocytes in the spinal cord. Overall,
MG1 and siRNA-IRF5 complexes were highlyeffective for the successful suppression of hyperalgesia-induced spi-
nal nerve injuries compared with that of other peptides or naked
siRNA. This ﬁnding highlights the potential use of the MG1 peptide
for developing targeting and delivery systems. IRF5 was identiﬁed as
a key molecule involved in neuropathic pain. Many molecules have
been reported to be associated with the pathogenesis of painful neu-
ropathy or neuropathic pain.66,67 Despite the multitude of drugs
that have been developed to treat neuropathic pain, an effective
medication has yet to be identiﬁed.67 In the present study, the selec-
tive suppression of IRF5 in microglia yielded effective results for
reducing neuropathic pain, highlighting the pivotal role that IRF5
may play in potential treatment strategies. Our results emphasize
the importance of recognizing IRF5 as a key factor in neuropathic
pain, as previously demonstrated.20
Figure 7. Gene Therapy for Neuropathic Pain Mice
Using theDelivery of siRNAwithHoming Peptides to
the Spinal Cord
(A) The effects of the mechanical threshold in the neuro-
pathic mice on the ipsilateral (ipsi) or contralateral sides by
the injection of CTR (buffer only) (n = 5), siRNA-IRF5 only
(1 mg/mouse, n = 5), and MG1+siRNA-IRF5 (peptide,
3 mg/mouse; siRNA, 1 mg/mouse; n = 10) on day 3 post-
transection. Error bars, mean ± SD. *p < 0.05 versus CTR-
ipsi and siRNA-ipsi. (B) Relative expression of IRF5 mRNA
in the spinal cord of the neuropathic pain mice on day 5
post-transection in CTR (buffer only) (n = 5), siRNA-IRF5
only of the low-dose group (siRNA-L) (1 mg/mouse, n = 5)
or the high-dose group (siRNA-H) (5 mg/mouse, n = 5),
and MG1+siRNA-IRF5 of the low-dose group (MG1+
siRNA-L) (peptide, 3 mg/mouse; siRNA, 1 mg/mouse;
n = 10) or the high-dose group (MG1+siRNA-H) (peptide,
15 mg/mouse; siRNA, 5 mg/mouse; n = 5). IRF5 mRNA
expression levels were standardized by b-actin mRNA
expression and were shown as the relative ratio against
the expression level at day 0 (n = 5) in the spinal cord. CTR,
control mice; MG, microglia-specific peptides. Error bars,
mean ± SD. *p < 0.05 versus CTR and another siRNA
group in the same dose. #p < 0.05. (C) The effects of the
mechanical threshold in the neuropathic pain mice on the
ipsilateral or contralateral sides due to the injection of CTR
(buffer only) (n = 6), MG1+siRNA-IRF5 (n = 6), MG2+
siRNA-IRF5 (n = 6), AS1+siRNA-IRF5 (n = 6), and
DRG+siRNA-IRF5 (n = 6) on day 3 post-transection. The
concentration of administered peptide or siRNA is 3 or
1 mg in each mouse, respectively. Error bars, mean ± SD.
*p < 0.05 versus all other ipsi groups. (D) The effects of the
mechanical threshold in neuropathic pain mice on ipsi-
lateral or contralateral sides by the high-dose injection of
CTR (buffer only) (n = 5), siRNA-IRF5 only (n = 5),
MG1+siRNA-IRF5 (n = 5), and MG2+siRNA-IRF5 (n = 5).
The concentration of administered peptide or siRNA is 15
or 5 mg in each mouse. Error bars, mean ± SD. *p < 0.05
versus all other ipsi groups. #p < 0.05 versus the CTR-ipsi
group. xp < 0.05.
www.moleculartherapy.orgThis study highlights the inhibition of IRF5 with microglia homing
peptides as a strategy for novel gene therapy for neuropathic pain
in mice. The complexes between peptides and siRNA-IRF5 inhibited
hyperalgesia induced by spinal nerve transection. The use of these
complexes in the spinal cord may be considered a promising method
for the treatment of neuropathic pain.
MATERIALS AND METHODS
Animals
C57BL/6 mice were purchased from Jackson Laboratories (Bar
Harbor, ME, USA). All animals were housed under a 12-hr
light:dark cycle and were provided with water and mouse chow
ad libitum. All animal experimental protocols were approved by
the Institutional Animal Care and Usage Committee (IACUC) at
Shiga University of Medical Science and were performed in accor-dance with the guidelines of the IACUC at Shiga University of
Medical Science.
Preparation of Cultured Cells
NSC-34 cells were purchased from CELLutions Biosystems (Toronto,
Canada) and were prepared as the representative neuronal cells. NSC-
34 cell lines were maintained with 10% fetal calf serum in DMEM/F12
medium (Thermo Fisher Scientiﬁc, Waltham, MA, USA). KT-5 cells
were obtained from the Japanese Collection of Research Bioresources
(JCRB) cell bank at the National Institutes of Biomedical Innovation,
Health and Nutrition. Ra2 and 6-3 cells were purchased from Cosmo
Bio (Tokyo, Japan). These cells were maintained in culture according
to the manufacturer’s protocol and were used to screen the homing
peptides. Primary cultures of astrocytes and microglia were pre-
pared from the brain tissue of C57BL/6 pups 1–2 days postpartum.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 211
Figure 8. Histological Analysis of the Spinal Cord in
Neuropathic Pain Mice after Gene Therapy
(A) Immunohistochemistry of IRF5 (green) and CD86 (red) in
the spinal cord tissues from L5 5 days after treatment with
the control buffer (CTR group), siRNA-IRF5 only (siRNA
group) (1 mg/mouse), and MG1+siRNA-IRF5 (MG1+siRNA
group) (peptide, 3 mg/mouse; siRNA, 1 mg/mouse). The left
three panels (high, high magnification) show the enlarge-
ment of the ipsilateral dorsal horns in the spinal cord at the
same section of the square portion of the panel farthest to
the right (low, low magnification). Scale bars, 100 mm.
Broken lines showed the margin of bilateral dorsal horns in
spinal cords. Contra, contralateral side; ipsi, ipsilateral side.
(B and C) Quantitative analysis of immunostainings in IRF5
(B) and CD86 (C). Bars showed the immunostaining intensity
of IRF5 or CD86 in the CTR, siRNA, or MG1+siRNA group
(n = 5 in each). Error bars, mean ±SD in (B) and (C). *p < 0.05
versus the CTR and siRNA groups.
Molecular Therapy: Nucleic AcidsAstrocytes were isolated by the passage of whole cells during the
initial 5–7 days. After a 14-day incubation of mixed culture cells, mi-
croglia began to grow on the astrocyte cell sheet and were isolated in
another culture dish. The isolated microglia were subsequently used
for experiments.
In Vivo and In Vitro Phage Display and Screening of Homing
Peptides Targeting Astrocytes and Microglia
The CX7C phage library was purchased from New England Biolabs
(Ipswich, MA, USA) and was used for both in vivo and in vitro phage
display to screen astrocyte or microglia homing peptides. The proto-
cols described by Christianson et al.68 were used with minor modiﬁ-
cations. The phage library was injected into C57BL/6 mice through
the tail vein at a titer of 109 plaque-forming units (pfu)/mL in
100 mL Tris-buffered saline (50 mM Tris-HCl [pH 7.5]). Five minutes
after the injections, whole spinal cords were isolated after the trans-
cardiac removal of blood. After the weights of the harvested spinal212 Molecular Therapy: Nucleic Acids Vol. 11 June 2018cord tissues were recorded, each sample was ho-
mogenized in DMEM (Thermo Fisher Scientiﬁc)
with protease inhibitor (Sigma-Aldrich, St. Louis,
MO, USA). Aliquots were introduced into Escher-
ichia coli ER2738 (New England Biolabs, Ipswich,
MA, USA), and the number of phages in the
spinal cord was titrated by plaque-forming units.
After ampliﬁcation to 109 pfu, the phages were
injected into a new cohort of C57BL/6 mice.
This process was performed three times to select
the speciﬁc phages that bound to the spinal cord.
After three rounds of in vivo panning in the spinal
cord, the phages were introduced separately to
cultured astrocyte (KT-5) or microglia cell lines
(6-3 cells for M1 [proinﬂammatory type] or Ra2
cells for M2 [anti-inﬂammatory type]) for
5 min, and three additional cycles of in vitropanning were performed for each cell line. In total, genomes were iso-
lated from a collection of 50–58 phages with high afﬁnities for each
cell line and then analyzed for DNA sequences coding for pIII protein.
Analysis of Binding of Homing Peptides to Astrocytes and
Microglia In Vitro and In Vivo
AS1(C-LNSSQPS-C), MG1(C-HHSSSAR-C), and MG2(C-
NTGSPYE-C) peptides were synthesized and labeled with FITC
by Invitrogen (Carlsbad, CA, USA). Isopropyl cyanide of FITC bound
with the N terminus of each peptide by the intermediary of aminocap-
roic acid linker. These peptides labeled with FITC were reﬁned to a
purity of >95% by high-performance liquid chromatography, and
their characteristics were conﬁrmed by mass spectrometry. For
in vitro experiments, the labeled peptides were applied to culture cells
(NSC-34 as representative neuronal cells, primary culture of astro-
cytes and microglia) at a concentration of 1 mg/mL in 200 mL of cul-
ture medium in 24-well plates. After 24 hr of incubation with the
www.moleculartherapy.orgpeptides, cells were ﬁxed with 4% paraformaldehyde (PFA) and were
prepared for immunocytochemistry with each primary antibody:
anti-MAP2 antibody (Merck Millipore, Darmstadt, Germany] for
neurons, anti-GFAP antibody (Promega, Maddison, WI, USA) for as-
trocytes, anti-Iba1 antibody (Wako Pure Chemical Industries, Osaka,
Japan) for microglia, anti-CD86 antibody (Abcam, Cambridge, UK)
for M1 microglia, and anti-CD206 antibody (Abcam) for M2 micro-
glia. Samples were subsequently incubated with species-matched
secondary antibodies (Alexa Fluor 555 antibody; Molecular Probes,
Eugene, OR, USA) to enable the visualization of stained cells with
confocal laser microscopy (C1si; Nikon, Tokyo, Japan) using EZC1
3.90 (Nikon). FITC-positive cells were identiﬁed, counted in six inde-
pendent wells, and calculated as the average of the percentage of pos-
itive staining cells in each peptide group. For microglia, CD86- and
CD206-positive cells were counted, and their percentages were calcu-
lated in MG1- or MG2-positive microglia from six independent wells.
In total, >1,000 cells were used for analysis. These in vitro experiments
were performed in triplicate.
For in vivo experiments, 3 mg of AS1, MG1, andMG2 peptides labeled
with FITC were separately injected into C57BL/6 mice through the
intrathecal space at a concentration of 300 ng/mL in 10 mL of PBS.
At 3 hr after the injection, the spinal cords were isolated from the
mice after transcardiac perfusion ﬁxation with 4% PFA. Sections of
the spinal cord were cut and incubated with anti-GFAP primary an-
tibodies (Promega) or anti-Iba1 primary antibodies (Wako Pure
Chemical Industries) overnight at 4C, washed, and then incubated
with species-matched secondary antibodies tagged with Alexa Fluor
555 (Molecular Probes). All sections were visualized under a
confocal laser microscope (C1si; Nikon) with EZC1 3.90 (Nikon).
These in vivo experiments were performed with ﬁve mice in each pep-
tide group.
Complex between Peptides and siRNA for Gene Delivery
MG1-3R (MG1[C-HHSSSAR-C]+GGG+3 arginine residue [R]),
MG1-6R (MG1[C-HHSSSAR-C]+GGG+6 arginine residue [R]),
MG1-9R, MG2-9R, AS1-9R (AS1[C-LNSSQPS-C]+GGG+9R), and
DRG-9R (DRG[C-SPGARAF-C]+GGG+9R)11 peptides were synthe-
sized by Invitrogen and the Peptide Institute (Osaka, Japan). These
peptides were reﬁned to a purity of >95% by high-performance liquid
chromatography, and their characteristics were conﬁrmed by mass
spectrometry. The DRG peptide, which was previously reported to
target the DRG neuron in mice, was prepared as a non-target control
in this study. siRNA-IRF5 duplexes were synthesized by OriGene
Technologies (Rockville, MD, USA), which consisted of 27-mer anti-
sense and 25-mer sense of the following sequence: 50-CGUAGACU
GAUAUAGCAAUGUGGTG-30. The fusion complexes between
peptides and oligonucleotides were formulated by electrostatic inter-
action, and an appropriate molecular ratio of peptides to oligonucle-
otides was decided upon by the visualization of those oligonucleotides
with ethidium bromide under UV excitation after electrophoresis in
agarose gels (Figure S1). The ﬁnal peptide-to-oligonucleotide molec-
ular weight ratio of 3:1 was used for the in vitro and in vivo knock-
down study. These electrophoreses were performed in triplicate.Knockdown Experiments by Gene Delivery with Peptide-siRNA-
IRF5 Complexes to Microglia
Primary cultures of microglia were prepared in 12-well plates
1 day before the experiments. The inﬂammation of the microglia
was induced by LPS (1 mg/mL). One hour after LPS stimulation,
MG1-9R+siRNA-IRF5, MG2-9R+siRNA-IRF5, or siRNA-IRF5 alone
was applied to the cells at low (peptide, 200 ng or none; siRNA, 66 ng)
or high (peptide, 1 mg or none; siRNA, 330 ng) doses. After a 3-hr
period, the effects of the treatment were evaluated by measuring
IRF5 mRNA expression with qRT-PCR (IRF5: forward primer
50-CAGGTGAACAGCTGCCAGTA-30, reverse primer 50-GGCCT
TGAAGATGGTGTTGT-30; b-actin: forward primer 50-ATGGAT
GACGATATCGCT-30, reverse primer 50-TCTGTCAGGTCCCGG
CCA-30) of each treatment group, in addition to the scrambled siRNA
oligonucleotide, negative-control groups (MG1-9R+siRNA-control,
MG2-9R+siRNA-control, or only siRNA-control) at the same dose
as the treatment groups. After treatment with the complexes (peptides
and oligonucleotides) for 24 hr, the cells were ﬁxed with 4% PFA and
incubated with IRF5 primary antibody for immunocytochemistry
(Abcam). Samples were then incubated with species-matched second-
ary antibodies (Alexa Fluor 555 antibody;Molecular Probes) to enable
the visualization of stained cells, and the immunostaining and phase
images were observed through confocal laser microscopy (C1si;
Nikon) with EZC1 3.90 (Nikon). Staining for IRF5 was quantiﬁed
by ImageJ 1.51 (NIH, Bethesda, MD, USA) using at least 5 indepen-
dent wells with low or high concentrations of peptide-siRNA com-
plexes. These in vitro knockdown experiments were performed in
triplicate.
Gene Therapy with Peptide-siRNA-IRF5 Complexes for
Neuropathic Pain after Spinal Nerve Transection
Gene therapy experiments were performed using a mouse model of
neuropathic pain, in which the spinal nerves of C57BL/6 mice were
transected at L5 on the left side (ipsilateral).69 The peptide and oligonu-
cleotide complexes (10mLof a 0.1MPBS solution including 3mg of pep-
tide [MG1-9R, MG2-9R, AS1-9R, or DRG-9R] and 1 mg of siRNA-
IRF5) were injected once into mice through the intrathecal space
3 days after transection. For the experiments using the high dose, the
peptide and oligonucleotide complexes of siRNA-IRF5 with MG1 or
MG2 were used at the same volume (10 mL) of 0.1 M PBS with 15 mg
of peptide and 5 mg of siRNA-IRF5. siRNA-IRF5- and buffer-only
groups were used as controls for all gene therapy experiments. Plantar
tests were performed before and after transection for 14 days to evaluate
the mechanical threshold on the ipsilateral side (left) and contralateral
side (right) by using a dynamic plantar aesthesiometer (Ugo Basil, Var-
ese, Italy). Pressure applied to the bilateral hindpaw served as the me-
chanical stimuli. The level of pressure was measured at the point of
paw withdrawal in response to the mechanical stimuli. The withdrawal
threshold was determined by the mean of three trials.
Five days after transection, a subset of mice was used to analyze the
efﬁcacy of gene delivery by MG1 peptides. Total mRNA was puriﬁed
from L1 to L5 spinal cord tissue, and transcript levels of the IRF5 gene
were measured by quantitative RT-PCR.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 213
Molecular Therapy: Nucleic AcidsFor the histological analysis of gene delivery with MG1 peptides, spi-
nal cords were sectioned after perfusion ﬁxation with 4% PFA on
day 5. The sections were incubated with anti-IRF5 primary antibodies
(Abcam) and anti-CD86 primary antibodies (Abcam) overnight at
4C, washed, and then incubated with species-matched secondary an-
tibodies tagged with Alexa Fluor 488 and Alexa Fluor 555 (Molecular
Probes). All sections were visualized under a confocal laser micro-
scope (C1si; Nikon) with EZC1 3.90 (Nikon). The ﬂuorescent inten-
sity of IRF5 and CD86 immunostaining was quantiﬁed by ImageJ 1.51
in the sections from ﬁve independent mice in each control, siRNA,
and MG1+siRNA group. The average was compared among those
three groups.
Statistical Analyses
Data are expressed as mean ± SD. All in vitro experiments were per-
formed in triplicate in at least three independent experiments. In vivo
analyses were performed using a minimum of ﬁve mice per group,
unless otherwise speciﬁed. Student’s unpaired two-tailed t tests
were performed to determine the signiﬁcant differences among the
treatment groups. For multiple datasets, one-way ANOVA and
Scheffe’s tests were used. p < 0.05 was considered statistically
signiﬁcant.
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